Extended Data Fig. 4: Serologic and clinical response in a patient with Jo-1 anti-synthetase syndrome to daratumumab therapy. | Nature Medicine

Extended Data Fig. 4: Serologic and clinical response in a patient with Jo-1 anti-synthetase syndrome to daratumumab therapy.

From: BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

Extended Data Fig. 4

A total of 9 doses of daratumumab were administered (1.8 g each: week 0, 1, 2, 3, 4, 6, 8, 10, 12) with dexamethasone premedication (20 mg initially, reduced subsequently to 8 mg). a, Serum creatinine kinase (CK) levels. b, C-reactive protein. c, Myoglobin level in the serum. d, Immunoglobulin G, e, Immunoglobulin A and, f, Immunoglobulin M levels in the serum. g, Muscle strength as indicated by Manual Muscle Testing 8 (MMT8) score. h, Health assessment score.

Back to article page